Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Dromer

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 1995
Trichoderma pseudokoningii as a cause of fatal infection in a bone marrow transplant recipientA Gautheret, F Dromer, J H Bourhis, et al.
Medical Mycology|February 28, 2002
Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South AfricaA S Karstaedt, H H Crewe-Brown, F Dromer
Molecular Microbiology|November 13, 2001
Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharideG Janbon, U Himmelreich, F Moyrand, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1996
Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study GroupF Dromer, S Mathoulin, B Dupont, et al.
Chest|January 1, 1988
Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigationsM Lévy, F Dromer, N Brion, et al.
Infection and Immunity|March 1, 1987
Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharideF Dromer, J Salamero, A Contrepois, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1990
Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomesF Dromer, J Barbet, J Bolard, et al.
Journal of Clinical Microbiology|April 3, 2001
Are two Cryptococcus neoformans strains epidemiologically linked?D Garcia-Hermoso, F Dromer, S Mathoulin-Pelissier, et al.
Journal of Clinical Microbiology|October 1, 1994
Molecular typing of Cryptococcus neoformans serotype D clinical isolatesF Dromer, A Varma, O Ronin, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1985
Effects of urinary pH on renal interactions between probenecid and cefsulodin in rabbitsF Dromer, A Contrepois, N Brion, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 1, 1995
Trichoderma pseudokoningii as a cause of fatal infection in a bone marrow transplant recipientA Gautheret, F Dromer, J H Bourhis, et al.
Medical Mycology|February 28, 2002
Cryptococcal meningitis caused by Cryptococcus neoformans var. gattii, serotype C, in AIDS patients in Soweto, South AfricaA S Karstaedt, H H Crewe-Brown, F Dromer
Molecular Microbiology|November 13, 2001
Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharideG Janbon, U Himmelreich, F Moyrand, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1996
Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study GroupF Dromer, S Mathoulin, B Dupont, et al.
Chest|January 1, 1988
Community-acquired pneumonia. Importance of initial noninvasive bacteriologic and radiographic investigationsM Lévy, F Dromer, N Brion, et al.
Infection and Immunity|March 1, 1987
Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharideF Dromer, J Salamero, A Contrepois, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1990
Improvement of amphotericin B activity during experimental cryptococcosis by incorporation into specific immunoliposomesF Dromer, J Barbet, J Bolard, et al.
Journal of Clinical Microbiology|April 3, 2001
Are two Cryptococcus neoformans strains epidemiologically linked?D Garcia-Hermoso, F Dromer, S Mathoulin-Pelissier, et al.
Journal of Clinical Microbiology|October 1, 1994
Molecular typing of Cryptococcus neoformans serotype D clinical isolatesF Dromer, A Varma, O Ronin, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1985
Effects of urinary pH on renal interactions between probenecid and cefsulodin in rabbitsF Dromer, A Contrepois, N Brion, et al.
Pageof 6